The benefits of Vaxzevria outweigh the risks for adults of all age groups
–
–
The EMA recommends continuing to use AstraZeneca vaccine as a second dose 4 to 12 weeks after the first dose.
The European Medicines Agency (EMA) has clarified the data on the risk of thrombosis when vaccinated with the coronavirus drug from AstraZeneca – Vaxzevria. This side effect can affect up to one in 100,000 people vaccinated, reported Online regulator on Friday, April 23rd.
The EMA says the Vaxzevria vaccine is effective in preventing hospitalizations and deaths from COVID-19, and its benefits outweigh the risks for adults of all age groups.
“The most common side effects are usually mild to moderate and go away after a few days. The most serious side effects are very rare cases of unusual blood clots with a low platelet count, which are estimated to occur in 1 in 100,000 people vaccinated,” the report said. …
The EMA also recommends continuing to use AstraZeneca vaccine as a second dose, 4-12 weeks after the first dose, according to the product information sheet.
Earlier this week, it became known that in France, eight people have died due to thrombosisafter vaccination with AstraZeneca. As of April 8, almost 2.8 million vaccinations had been made in the country. In total, since the beginning of the vaccination of the country’s population against COVID-19 with the drug AstraZeneca, 23 cases of thrombosis have been recorded in France.
News from Correspondent.net in Telegram. Subscribe to our channel https://t.me/korrespondentnet
– .
